Reference No: Author(s) Approval date: October committee. September Operational Date: Review:
|
|
- Samuel Simon
- 6 years ago
- Views:
Transcription
1 Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) guidelines for Thyroid cancer Dr Fionnuala Houghton Consultant Clinical Oncologist & Dr Lois Mulholland Consultant Clinical Oncologist Ownership: Approval by: Operational Date: NICaN NICaN Drugs & Therapeutics committee October 2016 Version No. 1.2 Supercedes 1.1 Links to other policies NICaN Thyroid SACT protocols Approval date: Next Review: October 2016 September 2018 Version control for drafts: Date Version Author Comments October 2013 September 2016 October Dr L Mulholland 1.1 Dr F Houghton & Dr L Mulholland Version 1.0 completed Radioiodine ablation & lenvatinib advice updated 1.2 Dr F Houghton Lenvatinib & vandetanib are both cost per case.
2 Authorisation of Systemic Anti-Cancer Therapy (SACT) Guidelines for Thyroid Cancer These SACT guidelines are being submitted by the author on behalf of the Head & Neck oncologists group. SACT for Thyroid Malignancies V1.2 Page 1 of 14
3 Contents 1. Staging 2. Prognosis 3. DTC Treatment overview Ablation Reassessment and follow up Treatment on relapse Risk stratification 4. MTC Treatment overview Systemic therapy 5. Anaplastic thyroid cancer 6. Lymphoma of thyroid 7. References SACT for Thyroid Malignancies V1.2 Page 2 of 14
4 INTRODUCTION Thyroid cancer is the most common of the endocrine malignancies and comprises around 1% of all malignancies. There are approximately 2000 new cases of thyroid cancer diagnosed in the UK each year. Pathological subtypes include papillary, follicular, medullary, anaplastic and lymphoma. Staging TX T0 T1 T1a T1b T2 T3 T4a Primary tumor cannot be assessed. No evidence of primary tumor. Tumor 2 cm in greatest dimension limited to the thyroid. Tumor 1 cm, limited to the thyroid. Tumor >1 cm but 2 cm in greatest dimension, limited to the thyroid. Tumor >2 cm but 4 cm in greatest dimension, limited to the thyroid. Tumor >4 cm in greatest dimension limited to the thyroid or any tumor with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues). Moderately advanced disease. Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T4b Very advanced disease. Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. c T4a Intrathyroidal anaplastic carcinoma. c T4b Anaplastic carcinoma with gross extrathyroid extension. NX N0 N1 N1a N1b Regional lymph nodes cannot be assessed. No regional lymph node metastasis. Regional lymph node metastasis. Metastases to Level VI (pretracheal, paratracheal, and prelaryngeal/delphian lymph nodes). Metastases to unilateral, bilateral, or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0 M1 No distant metastasis. Distant metastasis. SACT for Thyroid Malignancies V1.2 Page 3 of 14
5 Anatomical stage groupings Stage T N M Papillary or follicular (differentiated) YOUNGER THAN 45 YEARS I Any T Any N M0 II Any T Any N M1 45 YEARS AND OLDER I T1 N0 M0 II T2 N0 M0 III T3 N0 M0 T1 N1a M0 T2 N1a M0 T3 N1a M0 IVA T4a N0 M0 T4a N1a M0 T1 N1b M0 T2 N1b M0 T3 N1b M0 T4a N1b M0 IVB T4b Any N M0 Stage IVC Any T Any N M1 Medullary carcinoma (all age groups) I T1 N0 M0 II T2 N0 M0 T3 N0 M0 III T1 N1a M0 T1 N1a M0 T2 N1a M0 T3 N1a M0 IVA T4a N0 M0 T4a N1a M0 T1 N1b M0 T2 N1b M0 T3 N1b M0 T4a N1b M0 Stage IVB T4b Any N IVB T4b Any N M0 IVC Any T Any N M1 Anaplastic carcinoma c IVA T4a Any N M0 IVB T4b Any N M0 IVC Any T Any N M1 SACT for Thyroid Malignancies V1.2 Page 4 of 14
6 DIFFERENTIATED THYROID CANCER Differentiated thyroid cancer (DTC) is an umbrella term for papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) and comprises 85 % of all thyroid cancers. The current UK standard treatment for the majority of DTC includes thyroidectomy with or without lymph node dissection by a skilled thyroid surgeon followed by radioiodine remnant ablation and subsequent TSH suppression with levothyroxine. Radioiodine ablation Preparation Prior to radioiodine treatment patients can be withdrawn from thyroxine for 2-4 weeks or recombinant thyroid stimulating hormone (rtsh) can be given on the two consecutive days prior to treatment, to give a TSH level of greater than 30. Current BTA guidelines 3 recommend that rhtsh is used as the method of preparation for RRA in patients who have the following characteristics: pt1 to T3,pN0 or NX or N1, and M0 and R0 (no microscopic residual disease) Dose The standard dose of I 131 for ablation is 3.7GBq Based on the Hi-Lo and ESTIMABL data, an I 131 dose of 1.1 GBq can be considered for low-risk 4,5 disease. Patients are encouraged to follow a low-iodine diet prior to treatment. Work- up for I 131 Full blood count, Oncology profile (Specifically, calcium levels), Thyroid Function tests Baseline chest xray and ECG in selected patients Assessment of fitness to be in isolation for recommended time period Negative pregnancy test in females of child bearing potential. Routine antiemetics are given prior to the ablation and throughout their inpatient stay. Pre treating with dexamethasone should be considered for those with large volume disease particularly those with lung metastases Male patients should be offered sperm banking prior to a therapy dose. SACT for Thyroid Malignancies V1.2 Page 5 of 14
7 Written consent should be obtained by an ARSAC licence holder or delegate, to include benefits of treatment, radiation protection issues and acute and long term side effects including nausea, dry mouth, sialadenitis, lacrimal duct stenosis, fertility issues and low risk of second malignancy Patients will remain in isolation until levels of radioactivity are sufficiently low to allow discharge Patients should have a post treatment iodine scan within 7 days of ablation or treatment. Thyroid replacement should be restarted on discharge (T3 or T4). TSH Suppression Patients require TSH suppression with adequate doses of thyroxine. For low risk patients this suppression can be relaxed towards the normal range if they have a negative stimulated TG and USS at 1 year. TSH suppression can be relaxed in lower risk patients as demonstrated below. TSH <0.1 TSH TSH If patient has persistent disease Has had remnant ablation No persistent disease Intermediate or high risk disease Has not had remnant ablation Clinically disease free Tg stable USS neck normal OR Has had remnant ablation and low risk as per ATA Reassessment Patients are reassessed with either a radioiodine scan at 4-6 months or a stimulated thyroglobulin test at 9-12 months. An ultrasound scan of neck should be carried out at this time. SACT for Thyroid Malignancies V1.2 Page 6 of 14
8 A stimulated thyroglobulin is carried out by giving recombinant TSH 0.9mg on days 1 and 2 with a thyroglobulin level taken on day 5. If this is normal the patient is considered to be low risk and can be considered for annual review. A raised thyroglobulin under stimulation is suggestive of persistent or metastatic disease and further I 131 should be considered Follow up The purpose of regular, routine follow up of patients with DTC is to - detect recurrent disease - detect and manage toxicities from treatment with I ensure patients are on the appropriate dose of levothyroxine to maintain the appropriate level of TSH suppression - manage other associated problems including hypocalcaemia and monitoring of bone density Patients should be reviewed 2-3 months post ablation. This should comprise: Discussion of post treatment scan Thyroid function tests, thyroglobulin levels and serum calcium Review of toxicities post ablation Physical examination of thyroid bed and lymph nodes and thyroid status Review of thyroxine dose Follow up should be life long as the disease has a long natural history and late recurrences are not uncommon. Patients should be reviewed at least annually (more often for high risk disease) with physical examination, history, TFTs and thyroglobulin levels measured at each visit. For low and intermediate risk patients, frequency of follow up thereafter is usually 3-6 monthly for the first two years, 6-12 monthly years 3-5 and annually thereafter. Follow up of high risk patients is individualised to their needs. SACT for Thyroid Malignancies V1.2 Page 7 of 14
9 Very low risk patients who do not require long term TSH suppression can be discharged from specialist care after 5 to 10 years to community based follow up. Risk stratification The risk of recurrence of DTC can be stratified into low, intermediate and high. Designation to one of these risk groups will guide the intensity of follow up and level of TSH suppression that is required This is a dynamic process and level of risk may change for an individual with time as more information about their disease becomes available. ATA risk stratification Low risk Intermediate risk High risk No local or distant metastases Microscopic invasion of tumour Macroscopic tumour invasion into perithyroidal soft tissues at initial surgery All macroscopic tumour has been Cervical lymph node metastases or I131 Incomplete tumour resection resected uptake outside the thyroid bed on the post therapeutic WBS No tumour invasion Tumour with Distant metastases of locoregional tissues or structures aggressive histology or vascular invasion No aggressive histology or vascular invasion Thyroglobulinaemia out of proportion to what is seen on the postablative scan If I131 was given, no I131 uptake outside the thyroid bed on the post therapeutic WBS SACT for Thyroid Malignancies V1.2 Page 8 of 14
10 Treatment on relapse Locally recurrent disease should be treated surgically if possible. External beam radiotherapy is indicated when disease is unresectable and does not concentrate iodine sufficiently. Whilst disease remains iodine avid, repeated therapy doses of radioiodine may be used as local or systemic treatment. Metastatic disease should be treated with therapy doses of 5-7GBq. There is no evidence for use of recombinant TSH in this setting and patients should be withdrawn from thyroxine prior to treatment. Pre treating with dexamethasone should be considered for those with large volume disease particularly those with lung metastases. Patients should have a post treatment scan to assess for iodine uptake. The challenge in treating these patients arises when disease becomes refractory to iodine, usually as a consequence of the disease becoming less differentiated, which confers a very poor prognosis. First line treatment should be with a tyrosine kinase inhibitor, of which Lenvatanib has shown the biggest clinical benefit. A phase 3 trial showed PFS 18.3 months on levatanib versus 3.6 months on placebo. 6 Regime: Lenvatanib 24mg od D1-28 The tyrosine kinase inhibitor Sorafenib should be considered second line. A phase 3 trial showed PFS of 10.8 months on sorafenib versus 5.8 months on placebo. 7 Regime: Sorafenib 400 mg bd PO d1-28. No NICE guidance is currently available for targeted therapies, however there is positive SMC guidance and therefore funding is available on a cost per case basis. The SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sorafenib and lenvatinib. This advice is contingent upon the continuing availability of the PAS or a list price that is equivalent or lower. SACT for Thyroid Malignancies V1.2 Page 9 of 14
11 Third line, Chemotherapy Palliative chemotherapy has largely been superseded by targeted therapies (see above). It can however be considered in good performance status patients with rapidly progressive, symptomatic, 131I refractory, locally advanced or metastatic disease when targeted therapies are unavailable or have proved unsuccessful. The agents used are doxorubicin and cisplatin, but durable responses are uncommon. 3 MEDULLARY THYROID CANCER Medullary thyroid cancer (MTC) accounts for 5-10% of all thyroid cancers and 25% of these will be familial in origin. Standard management includes total thyroidectomy and central compartment node dissection, with selective bilateral neck dissection for those with T2-4 disease or clinically apparent nodes. 2 Radioiodine is not used in the management of MTC. For recurrent or metastatic disease, chemotherapy has essentially been ineffective. Radiolabelled Meta-Iodo-Benzyl_Guanadine (MIBG) or somatostatin analogues (eg Octreotide) have been used but not widely evaluated. Prognosis for these patients is limited, with 5 year survival rates of 25% and 10% of patients alive at 10 years. Tyrosine Kinase Inhibitors Vandetanib is currently the only drug with a European licence for use in advanced or metastatic medullary thyroid cancer and has demonstrated activity in Phase II trials. 7 Regime: Vandetanib 300 mg PO d1-30. (Available by IFR) SACT for Thyroid Malignancies V1.2 Page 10 of 14
12 ANAPLASTIC THYROID CANCER This is the least common and most aggressive subtype of thyroid cancer. Most patients present with advanced disease. Surgery is rarely indicated. These tumours do not take up radioiodine. External beam radiotherapy is the treatment of choice and treatment is often palliative. Radical Treatment Surgery is very rarely indicated as disease is usually advanced at presentation but thyroidectomy is carried out if possible followed by chemotherapy/radiotherapy as indicated. Palliative treatment Short courses of palliative radiotherapy may be useful for symptom control in locally advanced disease. Palliative chemotherapy: commonly used regimes include single agent doxorubicin or epirubicin, doxorubicin and cisplatin, paclitaxel and paclitaxel and carboplatin. 3 LYMPHOMA OF THYROID These cancers are usually managed by the lymphoma team and details of treatment can be found in the NICC lymphoma guidelines. Systemic therapy summary DTC Iodine sensitive disease- radioactive iodine Iodine resistant disease (palliative intent)- First line lenvatanib (IFR), Second line sorafenib (IFR), Third line doxorubicin 75mg/m2. MTC For progressive and symptomatic disease: SACT for Thyroid Malignancies V1.2 Page 11 of 14
13 Use of tyrosine kinase inhibitor within trial setting or Vandetanib (IFR). Anaplastic thyroid cancer Palliative: Doxorubicin 75mg/m 2 SACT for Thyroid Malignancies V1.2 Page 12 of 14
14 References 1. AJCC Cancer Staging Handbook, 7 th Ed 2. British Thyroid Association Guidelines, 2 nd Ed, British Thyroid Association Guidelines, 3 rd Ed, Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer, Mallick et al, N Engl J Med 2012;366: Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer, Schlumberger et al, N Engl J Med 2012; 366: Schlumberger M, et al. et al. Lenvatanib versus placebo in radioiodinerefractory patient s thyroid cancer: NEJM 372, 2015 (No.7). 7. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 31, 2013 (suppl; abstr 4) 8. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Jan 10;30(2): doi: /JCO Epub 2011 Oct Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, De Conti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid cancer. Cancer 1985;56: Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70: Hoskin PJ, Harmer CL. Chemotherapy for thyroid cancer. Radiother Oncol 1987;10: SACT for Thyroid Malignancies V1.2 Page 13 of 14
Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES
AJC 7/14/06 1:19 PM Page 67 Thyroid C73.9 Thyroid gland SUMMARY OF CHANGES Tumor staging (T) has been revised and the categories redefined. T4 is now divided into T4a and T4b. Nodal staging (N) has been
More information- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer
Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine
More informationAdjuvant therapy for thyroid cancer
Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationThe use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer
The use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer Wendy Sacks, M.D. Cedars Sinai Medical Center California Chapter Annual Meeting, AACE Nov 5, 2016 Increasing Incidence of Thyroid Cancer
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationThyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.
Thyroid Gland Protocol applies to all malignant tumors of the thyroid gland, except lymphomas. Procedures Cytology (No Accompanying Checklist) Partial Thyroidectomy Total Thyroidectomy With/Without Lymph
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationDifferentiated Thyroid Cancer: Initial Management
Page 1 ATA HOME GIVE ONLINE ABOUT THE ATA JOIN THE ATA MEMBER SIGN-IN INFORMATION FOR PATIENTS FIND A THYROID SPECIALIST Home Management Guidelines for Patients with Thyroid Nodules and Differentiated
More informationI-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Advances in Medical and Surgical Management of Thyroid Cancer January 23-24, 2015 I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER 2015 Leonard Wartofsky,
More informationCAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release
CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release 2 REVISION HISTORY Date Author / Editor Comments 5/19/2014 Jaleh Mirza Created the document 8/12/2014 Samantha Spencer/Jaleh
More informationReview Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update
Bangladesh J Otorhinolaryngol 2010; 16(2): 126-130 Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update Md. Abdul Mobin Choudhury 1, Md. Abdul Alim Shaikh
More informationAJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY-
TX: primary tumor cannot be assessed T0: no evidence of primary tumor Tis: carcinoma in situ. T1: tumor is 2 cm or smaller AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY- T2:
More informationA Review of Differentiated Thyroid Cancer
A Review of Differentiated Thyroid Cancer April 21 st, 2016 FPON Webcast Jonn Wu BMSc MD FRCPC Radiation Oncologist, Vancouver Centre Chair, Provincial H&N Tumour Group, BCCA Clinical Associate Professor,
More informationDisclosures Nodal Management in Differentiated Thyroid Carcinoma
Disclosures Nodal Management in Differentiated Thyroid Carcinoma Nothing to disclose Jonathan George, MD, MPH Assistant Professor UCSF Head and Neck Oncologic & Endocrine Surgery Objectives Overview Describe
More informationReoperative central neck surgery
Reoperative central neck surgery R. Pandev, I. Tersiev, M. Belitova, A. Kouizi, D. Damyanov University Clinic of Surgery, Section Endocrine Surgery University Hospital Queen Johanna ISUL Medical University
More informationHead & Neck Clinical Sub Group. Network Agreed Imaging Guidelines for UAT and Thyroid Cancer. Measure Nos: 11-1C-105i & 11-1C-106i
Greater Manchester, Lancashire & South Cumbria Strategic Clinical Network & Senate Head & Neck Clinical Sub Group Network Agreed Imaging Guidelines for UAT and Thyroid Cancer Measure Nos: 11-1C-105i &
More information1. Protocol Summary Summary of Trial Design. IoN
1. Protocol Summary 1.1. Summary of Trial Design Title: Short Title/acronym: IoN Is ablative radioiodine Necessary for low risk differentiated thyroid cancer patients IoN EUDRACT no: 2011-000144-21 Sponsor
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More information131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans
131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans Anca M. Avram, M.D. Associate Professor of Radiology Department of Nuclear Medicine University of Michigan Ann Arbor,
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Criteria Thyroid Carcinoma Variant 1: T1a N0 M0 papillary thyroid cancer: 40-year-old woman. 30 mci with thyrotropin 100 mci with thyrotropin 30 mci with thyroid hormone
More informationDifferentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment
ORIGINAL ARTICLE Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment Martínez MP, Lozano Bullrich MP, Rey M, Ridruejo MC, Bomarito MJ, Claus
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Thyroid Cancer pathway development worksheet, v9 April 13, 2015 Required Structured Data: Stage Staging Components Staging Date Histology Quality Measure(s): Staging (clinical or pathologic)
More informationTHYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine
THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?
More informationManagement of Recurrent Thyroid Cancer
Management of Recurrent Thyroid Cancer Eric Genden, MD, MHA Isidore Professor and Chairman Department of Otolaryngology- Head and Neck Surgery Senior Associate Dean for Clinical Affairs The Icahn School
More informationEuropean consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
European Journal of Endocrinology (2006) 154 787 803 ISSN 0804-4643 CONSENSUS STATEMENT European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
More informationTHYROID CANCER IN CHILDREN
THYROID CANCER IN CHILDREN Isabel ROCA, Montserrat NEGRE Joan CASTELL HU VALL HEBRON BARCELONA EPIDEMIOLOGY ADULTS males 1,2-2,6 cases /100.000 females 2,0-3,8 cases /100.000 0,02-0,3 / 100.000 children
More informationClinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA
Clinical Guidance in Thyroid Cancers Stephen Robinson Imperial at St Mary s On behalf of BTA Background to thyroid cancer Incidence probably increasing slowly 1971-95; 2.3 women 0.9 men /100,000 2001;
More informationCalcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
More informationDr J K Jekel Dept. Surgery University of Pretoria
Dr J K Jekel Dept. Surgery University of Pretoria No Maybe ( T`s and C`s apply ) 1. Total thyroidectomy 2. Neck dissection only if nodes are involved 3. Ablative dose or doses of Radioactive Iodine 4.
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationRadiation Therapy for Thyroid Cancer. When is Radiation Therapy indicated in Thyroid Cancer of Follicular or Parafollicular Cell Origin?
When is Radiation Therapy indicated in Thyroid Cancer of Follicular or Parafollicular Cell Origin? Jeanne Marie Quivey MD FACR October 200 Radiation Therapy for Thyroid Cancer Radioactive 3- I (RAI) External
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More informationRisk Adapted Follow-Up
Risk Adapted Follow-Up Individualizing Follow- Up Strategies R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Medical College
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationThyroid Cancer. With 51 Figures and 30 Tables. Springer
H.-J. Biersack F. Griinwald (Eds.) Thyroid Cancer With 51 Figures and 30 Tables Springer PART 1 Basics 1 The Changing Epidemiology of Thyroid Cancer 3 R. GORGES 1.1 Basic Epidemiological Problems in Thyroid
More informationPediatric Thyroid Cancer Lung Metastases. Liora Lazar MD
Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers
More informationSuccess rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan
ORIGINAL ARTICLE Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan I. Hommel 1 *, G.F. Pieters 1, A.J.M. Rijnders 2, M.M. van Borren 3, H. de
More informationL ARYNX S TAGING F ORM
CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left
More informationYCN Thyroid NSSG. *** VALID ON DATE OF PRINTING ONLY - all guidelines available at *** page 1 of 8 version number: 1.
YCN Thyroid NSSG Guidelines on Indications for Thyroid Surgery, Prophylactic Level 6 and Radioiodine plus follow-up of low risk differentiated thyroid cancer page 1 of 8 i Document Control Title Author(s)
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationEsophagus Stomach 4/2/15
Collecting Cancer Data: Larynx & Thyroid 2014-2015 NAACCR Webinar Series May 7, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants
More informationThyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationWhat you need to know about Thyroid Cancer
What you need to know about Thyroid Cancer This booklet has been designed to help you to learn more about your thyroid cancer. It covers the most important areas and answers some of the frequently asked
More informationThyroid. At-A-Glance. Papillary or follicular (differentiated) UNDER 45 YEARS Stage I Any T Any N M0 Stage II Any T Any N M1
8 Thyroid At-A-Glance S U M M A R Y O F C H A N G E S Tumor staging (T1) has been subdivided into T1a ( 1 cm) and T1b ( 1 2 cm) limited to thyroid The descriptors to subdivide T categories have been changed
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationReview Article Management of thyroid carcinoma Alauddin M, Joarder AH
Management of thyroid carcinoma Alauddin M, Joarder AH The ORION Medical Journal 2004 May;18:163-166 Overview The two most common forms of thyroid cancer, papillaryand follicular thyroid cancer, together
More informationThis form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationHow good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status
New Perspectives in Thyroid Cancer Jennifer Sipos, MD Assistant Professor of Medicine Division of Endocrinology The Ohio State University Outline Thyroid Nodules Thyroid Cancer Epidemiology Initial management
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationDifferentiated Thyroid Carcinoma
Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University
More informationRESEARCH ARTICLE. Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131 I Ablation Therapy for Differentiated Thyroid Cancer
RESEARCH ARTICLE Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131 I Ablation Therapy for Differentiated Thyroid Cancer Zekiye Hasbek 1 *, Bulent Turgut 1, Fatih Kilicli 2,
More informationThyroid Cancer: Imaging Techniques (Nuclear Medicine)
Thyroid Cancer: Imaging Techniques (Nuclear Medicine) Andrei Iagaru, MD MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology Introduction Ø There are
More information10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary
Surgery for Well-differentiated Thyroid Carcinoma- The Primary Head and Neck Endocrine Surgery Department of Otolaryngology-Head and Neck Surgery, UCSF October 24-25, 2008 Robert A. Sofferman, MD Professor
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationOral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi
Oral cancer: Prognosis & Treatment Dr. Hani Al Sheikh Radhi Prognostic factors in Oral caner TNM staging T stage N stage M stage Site Histological Factors Vascular & Perineural Invasion Surgical Margins
More informationCase 4: Disseminated bone metastases from differentiated follicular thyroid cancer
Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) Disseminated bone
More informationThyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.
ORIGINAL ARTICLE Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma. Md. Sayedur Rahman Miah, Md. Reajul Islam, Tanjim Siddika Institute of Nuclear Medicine & Allied Sciences,
More informationEvaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient
Evaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient Linda Stachowiak MS/CCCSLP BCS-S Speech Pathology Oncology Specialist UFHealth Cancer Center at Orlando Health Orlando Florida
More informationI treatment for differentiated thyroid carcinoma Current guidelines
131 I treatment for differentiated thyroid carcinoma Current guidelines François Jamar, UCL Brussels francois.jamar@uclouvain.be IAEA-Belnuc Theranostics course Brussels, October 5 th, 2017 131 I treatment
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationManagement Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 16, Number 2, 2006 American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Taskforce*
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationThyroid Cancer & rhtsh: When and How?
Thyroid Cancer & rhtsh: When and How? 8 th Postgraduate Course in Endocrine Surgery Capsis Beach, Crete, September 21, 2006 Quan-Yang Duh, Professor of Surgery, UCSF Increasing Incidence of Thyroid Cancer
More informationStrategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer
Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer A rational approach to longterm follow-up based on dynamic risk assessment. World Congress on Thyroid
More informationExternal Beam Radiation Therapy for Thyroid Cancer
External Beam Radiation Therapy for Thyroid Cancer C. Jillian Tsai, M.D, PH.D. Assistant Attending Director of Head and Neck Cancer Research Department of Radiation Oncology Memorial Sloan Kettering Cancer
More informationCorrespondence should be addressed to Stan H. M. Van Uum;
Oncology Volume 2016, Article ID 6496750, 6 pages http://dx.doi.org/10.1155/2016/6496750 Research Article Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive
More informationDiagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer
European Journal of Endocrinology (2004) 150 649 653 ISSN 0804-4643 CLINICAL STUDY Diagnostic 131 I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer Henry Taylor,
More informationThyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?
Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting? Jacob Moalem, MD, FACS Associate Professor Endocrine Surgery and Endocrinology URMC Agenda 1. When is lobectomy alone
More informationCase-Based Discussion of Thyroid Cancer Therapy
Case-Based Discussion of Thyroid Cancer Therapy Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology The Ohio State University Co-Leader, Molecular Biology
More informationRadioiodine-refractory DTC
Oncology: Radioiodine-refractory DTC New Developments in Giuseppe COSTANTE, MD, Head, Endocrinology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Targeted Therapies Targeted Treatments
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationLocally advanced papillary thyroid cancer
Locally advanced papillary thyroid cancer Educational Session 12 th October 2015 Presenters: Smith JA, Carr-Boyd E Supervisors: Palme CE, Elliott M, Navin N, Gupta R Content Case report Imaging Primary
More information저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다.
저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,
More informationWhat is Thyroid Cancer? Here are four types of thyroid cancer:
What is Thyroid Cancer? Thyroid cancer is a group of malignant tumors that originate from the thyroid gland. The thyroid is a gland in the front of the neck. The thyroid gland absorbs iodine from the bloodstream
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationImaging in Thyroid Cancer
Imaging in Thyroid Cancer Susan J. Mandel MD MPH University of Pennsylvania School of Medicine Philadelphia, PA I-123 Ultrasound Background Radioiodine ablation of thyroid remnants after surgery is a generally
More informationAnca M. Avram, M.D. Professor of Radiology
Thyroid Cancer Theranostics: the case for pre-treatment diagnostic staging 131-I scans for 131-I therapy planning Anca M. Avram, M.D. Professor of Radiology Department of Nuclear Medicine University of
More informationShifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer
DEBATE WJOES Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer Ashok R Shaha
More informationThyroid carcinoma. Assoc. prof. V. Marković, MD, PhD Assoc. prof. A. Punda, MD, PhD D. Brdar, MD, nucl. med. spec.
Thyroid carcinoma Assoc. prof. V. Marković, MD, PhD Assoc. prof. A. Punda, MD, PhD D. Brdar, MD, nucl. med. spec. Thyroid tumors PRIMARY TUMORS Tumors of the follicular epithelium : - Tumors of the follicular
More informationLong Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience
Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience Geoffrey B. Thompson, MD Professor of Surgery College of Medicine, Mayo Clinic Differentiated Thyroid Cancer Objectives Overview
More informationManagement guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007
Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung
More information14 Clinical Review Volume 2 No. 1, 2004
14 Clinical Review Volume 2 No. 1, 2004 CLINICAL REVIEW Well-Differentiated Thyroid Carcinoma: A Review of the Available Follow-Up Modalities Taryn Davids, MD Ally P.H. Prebtani, MD ABSTRACT Well-differentiated
More informationA Risk-Adapted Approach to the Use of Radioactive Iodine and External Beam Radiation in the Treatment of Well-Differentiated Thyroid Cancer
Both radioactive iodine and external beam radiation can play roles in well-differentiated thyroid cancer. Rebecca Kinkead. Hula No. 3 (detail), 2010. Oil on canvas, 45 37. A Risk-Adapted Approach to the
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More information6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationIni7al Staging of Follicular Cell-derived Thyroid Cancers: the ATA 2015 IRS and AJCC 8th Ed. Cancer Staging Systems
12/25/17 9th Annual AACE Advances in Thyroid Cancer Course Tempe, Arizona January 12-13, 2018. Ini7al Staging of Follicular Cell-derived Thyroid Cancers: the ATA 2015 IRS and AJCC 8th Ed. Cancer Staging
More informationAJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx
AJCC Cancer Staging 8 th edition Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC 7 th edition Lip and Oral cavity Pharynx Larynx KEY CHANGES Skin of head and neck (Vermilion of the lip)
More informationRESEARCH ARTICLE. Comparison of Presentation and Clinical Outcome between Children and Young Adults with Differentiated Thyroid Cancer
RESEARCH ARTICLE Comparison of Presentation and Clinical Outcome between Children and Young Adults with Jian-Tao Wang 1,2&, Rui Huang 1&, An-Ren Kuang 1 * Abstract Background: The aim of the present study
More informationHow Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017
How Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017 Bryan R. Haugen, MD University of Colorado, School of Medicine Outline Some statistics New guidelines
More informationCANCERS OF THE ENDOCRINE ORGANS RARE THYROID CANCERS PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES
CANCERS OF THE ENDOCRINE ORGANS RARE THYROID CANCERS PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES Coordinator: Giuseppe COSTANTE (Endocrinology, Institut Jules Bordet), Ahmad AWADA (Medical
More information